Dianthus Therapeutics (DNTH)

The company’s lead programme is claseprubart, also known as DNTH103, a next-generation complement therapeutic designed to selectively inhibit active C1s in the classical complement pathway. By targeting active C1s rather than broadly suppressing the complement cascade, Dianthus seeks to reduce disease-driving immune activity while preserving more of the body’s normal immune defence. The candidate is being developed for severe autoimmune conditions where classical pathway activation is believed to play an important role.

Dianthus does not yet market approved products, so its investment profile is tied closely to clinical development progress, regulatory milestones, trial data, and its ability to finance research through the stages required for approval. As with many biotechnology companies at this stage, the business is centred on research and development rather than product revenue.

The company is led by executives with biotechnology and pharmaceutical experience, and it operates as a focused single-segment business. Its strategy is to build a differentiated autoimmune disease pipeline around precision complement inhibition, with the goal of offering less burdensome and potentially more effective treatment options for patients with rare or severe immune-mediated disorders.